Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Budesonide for Altitude Illness Prevention
NCT02941510Phase 3Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Mar 2017
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of budesonide in Altitude sickness (AMS), sponsored by University of Colorado Denver. Primary endpoints: Changes in Inflammation at 18 hours and Incidence of Acute Mountain Sickness at 18 hours. Planned start Mar 2017; status: withdrawn.
02
Drugs
budesonide
03
Conditions
Altitude sickness (AMS)
Beyond the preview
Go deeper on NCT02941510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941510.